09.09.19

EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific Meeting

Source: EyePoint Pharmaceuticals

07.25.19

EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code for Yutiq

Source: EyePoint Pharmaceuticals

07.08.19

EyePoint Pharmaceuticals Announces US Commercialization of Dexycu

Source: EyePoint Pharmaceuticals

06.10.19

EyePoint Pharmaceuticals Names New Members of Executive Leadership Team

Source: EyePoint Pharmaceuticals

05.01.19

EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVO

Source: EyePoint Pharmaceuticals

03.12.19

EyePoint Pharmaceuticals Announces US Commercial Launch of Dexycu

Source: EyePoint Pharmaceuticals

02.04.19

EyePoint Pharmaceuticals Announces US Commercial Launch of Yutiq

Source: EyePoint Pharmaceuticals

01.28.19

EyePoint Pharmaceuticals Appoints David Guyer, MD, to Board of Directors

Source: EyePoint Pharmaceuticals

01.03.19

EyePoint Pharmaceuticals to Launch Dexycu and Yutiq in First Quarter of 2019

Source: EyePoint Pharmaceuticals

12.17.18

EyePoint Pharmaceuticals Added to NASDAQ

Source: EyePoint Pharmaceuticals

View more stories